Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Conditions

• Kidney Tumor
• Renal Benign Neoplasm
• Renal Malignant Tumor

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors. To estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC. Participants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.

Key Dates

Start date

Feb 1, 2023

Status verified

Mar 2025

Primary completion

Feb 28, 2033

Completion

Dec 31, 2033

Study Design

Enrollment

100 participants (estimated)

Primary Outcome Measure

Histologic Classification (malignant vs. benign) [ Time Frame: Until surgical extirpation or 1 year repeat biopsy ]

Central Contacts

• Gopal N Gupta, MD
  708-216-8467
  [email protected]
• Agnes Natonton
  708-327-3295
  [email protected]

Locations (1)

Find similar trials in Maywood, IL

Related Studies

• Decision Aid (DA) for Renal Patients
  Recruiting · NYU Langone Health · New York, New York